Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer O'Sullivan

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
British Journal of Sports Medicine|September 29, 2020
Competitive sport, therapy, and physical education: voices of young people with cerebral palsy who have high support needsEimear Enright, Emma M Beckman, Mark J Connick, et al.
British Journal of Haematology|March 22, 2021
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centrePaul Deschamps, Mufaddal Moonim, Deepti Radia, et al.
Journal of the American Veterinary Medical Association|November 2, 2021
Osteomyelitis in cold-stunned Kemp's ridley sea turtles (Lepidochelys kempii) hospitalized for rehabilitation: 25 cases (2008-2018)Ashley L Powell, Kathryn A Tuxbury, Julie M Cavin, et al.
Haematologica|January 5, 2023
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosisClaire Harrison, Abdulraheem Yacoub, Bart Scott, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
British Journal of Haematology|March 15, 2021
Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Patrick Harrington, Claire N Harrison, Richard Dillon, et al.
Hemasphere|August 12, 2024
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasmsAndrea Duminuco, Joshua Au Yeung, Raj Vaghela, et al.
Leukemia Research Reports|January 2, 2023
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)Jumoke Okikiolu, Claire Woodley, Llywelyn Cadman-Davies, et al.
Hemasphere|July 8, 2021
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral CenterAlesia Khan, Claire Woodley, Deepti Radia, et al.
Haematologica|January 25, 2024
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trialSrdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
British Journal of Sports Medicine|September 29, 2020
Competitive sport, therapy, and physical education: voices of young people with cerebral palsy who have high support needsEimear Enright, Emma M Beckman, Mark J Connick, et al.
British Journal of Haematology|March 22, 2021
Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centrePaul Deschamps, Mufaddal Moonim, Deepti Radia, et al.
Journal of the American Veterinary Medical Association|November 2, 2021
Osteomyelitis in cold-stunned Kemp's ridley sea turtles (Lepidochelys kempii) hospitalized for rehabilitation: 25 cases (2008-2018)Ashley L Powell, Kathryn A Tuxbury, Julie M Cavin, et al.
Haematologica|January 5, 2023
Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosisClaire Harrison, Abdulraheem Yacoub, Bart Scott, et al.
Leukemia|July 24, 2025
QRISK3 score is predictive of thrombotic risk in patients with myeloproliferative neoplasmsAndrea Duminuco, Raj Vaghela, Sukhraj Virdee, et al.
British Journal of Haematology|March 15, 2021
Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)Patrick Harrington, Claire N Harrison, Richard Dillon, et al.
Hemasphere|August 12, 2024
Development of a natural language processing pipeline for assessment of cardiovascular risk in myeloproliferative neoplasmsAndrea Duminuco, Joshua Au Yeung, Raj Vaghela, et al.
Leukemia Research Reports|January 2, 2023
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)Jumoke Okikiolu, Claire Woodley, Llywelyn Cadman-Davies, et al.
Hemasphere|July 8, 2021
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral CenterAlesia Khan, Claire Woodley, Deepti Radia, et al.
Haematologica|January 25, 2024
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: stage 2 of a phase II trialSrdan Verstovsek, Moshe Talpaz, Martha Wadleigh, et al.
Pageof 4